



Sam E. Khan

Partner

New York
New Jersey

T: +1 646.414.6796 (NY) / +1 973.597.6372 (NJ) | F: +1 973.597.6373
skhan@lowenstein.com

Sam Khan is often the first call his clients make when facing complex transactional challenges. He has represented a diverse range of clientele, including financial institutions, private equity and venture capital funds, large and middle market pharmaceutical companies, global chemical manufacturers, and media and entertainment businesses.

Sam concentrates his practice on mergers and acquisitions, joint ventures, strategic and commercial transactions, and also counsels clients on general corporate matters. Additionally, Sam has a wealth of experience in complex leveraged finance transactions, and restructuring and private investment transactions.

In every engagement, Sam relies on his sound business judgement and wealth of experience across a wide range of industries to provide his clients with practical and efficient advice, with a singular focus on their near and long-term business goals.

EXPERIENCE

- > Representing Indorama Ventures (BKK:IVL) in its \$2.1 billion acquisition of the specialty chemicals portfolio of Huntsman Corporation USA (NYSE:HUN).
- > Represented Indorama Ventures Corpus Christi Holdings LLC (subsidiary of Indorama Ventures Public Company Limited) in a joint venture between Indorama Ventures Corpus Christi Holdings LLC, DAK Americas, LLC (a subsidiary of the chemicals manufacturer Alpek S.A.B. de C.V. (BMV: ALFAA)), and APG Polytech USA Holdings, Inc. (a subsidiary of Far Eastern New Century Corporation (TT: 1402)), in the acquisition, through a bankruptcy auction, of a Corpus Christi, Texas-based PTA-PET plant from M&G USA Corp. (a subsidiary of M&G Chemicals), for a purchase price and capital contributions in the sum of \$1.125 billion.
- > Represented Indorama Ventures Public Company Limited (BKK:IVL) as co-counsel with Mattos Filho in its acquisition of M&G Polimeros Brazil S.A., owner of Brazil's largest PET (polyethylene terephthalate) facility.
- > Represented Covis Pharma B.V., a global specialty pharmaceutical company and portfolio company of Cerberus Capital Management, in its acquisition of certain assets from AstraZeneca AB for a closing cash purchase price of \$350 million, in addition to conditional sales-related payments of up to \$21 million.
- > Representing Indorama Ventures Public Company Limited (BKK:IVL) as co-counsel with Allen & Overy in its pending acquisition of DuPont Teijin Films. Lowenstein is leading the US components of the acquisition.
- > Represented Covis Pharma S.á.r.l and Covis Injectables S.á.r.l, global specialty pharmaceutical companies and portfolio companies of Cerberus Capital Management, in their all-cash \$1.2 billion sale of assets to Concordia Healthcare Corp (TSX: CXR).
- > Represented BASF Corporation in the sale of its Polyolefin Catalysts business to W.R. Grace & Co., including BASF's related technologies and production plants in Pasadena, Texas and Tarragona Spain.
- > Represented Metalico Inc. (MEA), one of the nation's largest scrap metal recyclers, in its execution of the merger agreement for the \$102 million all-cash sale to Total Merchant Limited.
- > Represented Indorama Ventures Public Company Limited in its acquisition from BP Amoco Chemical Company of a 1,000-acre manufacturing facility located in Decatur, Alabama, which produces 1 million metric tons of annual purified terephthalic acid (PTA) capacity and 732,000 metric tons of paraxylene (PX) capacity.
- > Represented Crown Laboratories, Inc., a portfolio company of Hildred Capital Partners, LLC, in its acquisition of the North American distribution rights of five OTC consumer brands from GlaxoSmithKline.
- > Represented Crown Laboratories, Inc., a portfolio company of Hildred Capital Partners, LLC, in its acquisition of Vita Liberata, an Irish maker of sunless tanning and skincare products.
- > Represented Medical Specialties Distributors, LLC, a New Mountain Capital portfolio company, in its acquisition of First Choice Medical Holdings, Inc.
- > Represented BASF in its acquisition of Verenum Corp., a San Diego-based enzyme biotechnology company.

HONORS & AWARDS

> **The M&A Advisor: THE M&A ADVISOR'S 14th ANNUAL TURNAROUND AWARDS (2019)**

Chapter 11 restructuring of M&G Chemicals named winner of "Cross-Border Restructuring of the Year"

Chapter 11 reorganization of New England Motor Freight (NEMF) named winner of "Restructuring of the Year (\$25M to \$50M)"

NEWS & INSIGHTS

In the Media

> August 7-9, 2019

Lowenstein Sandler's representation of Thailand's leading global chemical company, Indorama Ventures (IVL), in its \$2.1 billion acquisition of Huntsman's chemicals units was featured in numerous media outlets including *The Wall Street Journal* and *The Deal*, which highlighted **Nicholas San Filippo IV**'s role in the transaction and previous work with IVL since 2003. *The Nation Thailand* called the transaction "a game changing acquisition for IVL, its largest ever and one of the biggest by a Thai company in the last decade." The acquisition was also featured **Bloomberg Law – Big Law Business**, *The Deal*, *The Associated Press*, the *Global Legal Chronicle*, *Business Wire*, *citybizlist*, *Bakersfield.com*, *The American Lawyer*, and *Law360*. The Lowenstein Sandler deal team included **Nicholas San Filippo IV**, **Sam E. Khan**, **Stuart S. Yusem**, **Nicholas G. Mehler**, **Christine Osvald-Mruz**, **Doreen M. Edelman**, **Brian Silikovitz**, **Norman W. Spindel**, **Mark S. Heinzelmann**, **Mitchell McDonald**, **Megan Monson**, **Sami Najib**, **Sunita Patel**, **Alex H. Rosenthal**, and **Niral T. Shah**. The Valence Group acted as exclusive financial adviser to IVL, and KPMG provided financial due diligence support. (*subscription required to access certain content*) [View Lowenstein's news announcement about this transaction.](#)

> May 1; May 25, 2019

Morningstar Inc., *Yahoo Finance*, *BioSpace*, *Cision PR Newswire*, *Chain Drug Review*, and the *Global Legal Chronicle* note Lowenstein Sandler as counsel to Crown Laboratories, Inc. and Hildred Capital Partners LLC in Crown's acquisition of the North American distribution rights to Keri from GlaxoSmithKline plc (NYSE: GSK). (Lowenstein deal team: **Herschel S. Weinstein**, **Sam E. Khan**, **Mitchell McDonald**, **James C. Shehan**, **Matthew P. Hintz**, **Michael A. Buxbaum**, **Matthew Tippy**, **Erica Perlmutter**, **Jeffrey M. Shapiro**, and **Jack Sidorov**.) [View Lowenstein's news announcement about this transaction.](#)

> November 30 - December 3, 2018

Business Wire, *MarketWatch*, *Pharmaceutical Business Review*, *Cosmetics Technology*, *ABF Journal*, *Cision PR Newswire*, and the *Tallahoma News* note Lowenstein Sandler as counsel to Crown Laboratories, Inc. (Crown Laboratories) and Hildred Capital Partners, LLC in Crown Laboratories' acquisition of the North American distribution rights of five OTC consumer brands from GlaxoSmithKline plc (NYSE: GSK). (Lowenstein deal team: **Herschel S. Weinstein**, **Sam E. Khan**, **Mitchell McDonald**, **Sunita Patel**, **James C. Shehan**, **Matthew P. Hintz**, **Sofia Kopelevich**, **Michael A. Buxbaum**, **Nicholas Gonski**, **Matthew Tippy**, **Jeffrey M. Shapiro**, and **Jack Sidorov**. [View Lowenstein's news announcement about this transaction.](#)

> September 27-30, 2018

Business Wire, *Compelo Ltd.*, and *citybizlist* note Lowenstein Sandler as legal counsel to Crown Laboratories, Inc. and Hildred Capital Partners, LLC in Crown's acquisition of Bellus Medical, which will become the new Aesthetics Division of Crown Laboratories. (Lowenstein deal team led by **Sam E. Khan** and **Herschel S. Weinstein**.)

EDUCATION

> Harvard Law School (J.D. 2009)

> The University of Texas at Austin (B.A. 2005), Philosophy, History, and Arabic Language and Literature; summa cum laude; Phi Beta Kappa

ADMISSIONS

> New York

> New Jersey